Core Insights - The company's bfLEAP® platform has demonstrated a significant increase in mean survival rates for pancreatic cancer patients, showing an almost threefold improvement from control to treatment arms [1][3][4] - Data from the pancreatic cancer trial will be presented at the 2026 ASCO GI symposium and subsequently published in the Journal of Clinical Oncology [2] Company Overview - BullFrog AI Holdings, Inc. utilizes artificial intelligence and machine learning to transform complex biomedical data into actionable insights, aiming to enhance drug discovery and development [6] - The company collaborates with leading research institutions to apply causal AI and its proprietary platforms, bfLEAP® and bfPREP™, to analyze complex clinical datasets [6] Research Findings - The study focused on glufosfamide, an investigational chemotherapeutic agent, and identified key biomarkers that contributed to the increased survival rates in pancreatic cancer patients [3][4] - The research concluded that data-driven clustering approaches can effectively refine patient stratification and guide personalized treatment strategies [4]

Highlights significant progress in 2025 and outlines commercial priorities and potential catalysts entering 2026GAITHERSBURG, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the release of its annual letter to shareholders, which highlights progre ...